AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

Linked entities

Linked entities (4)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 4

cancerLung Non-Small Cell Carcinomacivic_curation1.00
drugOsimertinibcivic_curation1.00
geneEGFRcivic_curation1.00
variantEGFR T790Mcivic_curation1.00

Curated evidence

Evidence citing this paper (2)

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR T790M2
Osimertinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID965 This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and wer… (full text at CIViC) PMID 25923549 · Jänne et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	rejected	EID2166 In a prospective study (NCT01802632) of 253 locally advanced or metastatic, non-small cell lung cancer patients, patients with EGFR T790M mutations treated with osimertinib were associated with improv… (full text at CIViC) PMID 25923549 · Jänne et al., 2015 · Open in CIViC	civic